NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
NovaBridge Biosciences (Nasdaq: NBP) announced it will host a webcast on Thursday, August 20, 2026, at 9:00 AM ET / 9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NovaBridge Biosciences (Nasdaq: NBP) announced it will host a webcast on Thursday, August 20, 2026, at 9:00 AM ET / 9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.
Investors can access the live and archived webcast via the Upcoming Events section of the Investors page on the NovaBridge website, with separate links for China and other locations. A replay will be available for at least 30 days after the event.
NovaBridge is a global biotechnology company with clinical programs in oncology and ophthalmology, led by candidates givastomig and VIS-101, and focuses on advancing differentiated therapeutic opportunities through tailored development, financing, and partnering strategies.
Details
Market move: NBP +3.16% in the Aug 14 session. 1H26 earnings report
On Aug 14, the first trading day after this news, NBP closed 3.16% above the previous close.
Data tracked by StockTitan Argus for the Aug 14 session.
Key Figures
- Announcement date
- August 13, 2026
- Company announcement dateline
- Webcast date
- August 20, 2026
- Scheduled corporate update and financial results webcast
- Reporting period end
- June 30, 2026
- First half 2026 financial results
- Webcast time
- 9:00 AM ET
- August 20, 2026 webcast
- China webcast time
- 9:00 PM China Standard Time
- August 20, 2026 webcast
- Replay availability
- at least 30 days
- Archived webcast replay
Historical Context
-
Annual meeting date, voting eligibility, and shareholder materials were announced.
-
Srishti Gupta became CEO and board member effective July 1, 2026.
-
Givastomig received FDA Fast Track Designation in gastric cancer.
-
Management scheduled a presentation at the Jefferies healthcare conference.
-
Management announced participation in the H.C. Wainwright investor conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
oncology medical
ophthalmology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that it will hold a webcast on Thursday, August 20, 2026 at 9:00 AM ET/9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.
Webcast Information:
- Date: Thursday, August 20, 2026
- Time: 9:00 AM ET/9:00 PM China Standard Time
- Web Access - China: Click here
- Webcast Access – All other locations: Click here
The live and archived webcast can also be accessed by visiting the NovaBridge Biosciences website on the Upcoming Events section of the Investors page. A replay of the webcast will be archived for at least 30 days after the event.
About NovaBridge
NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology.. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing, and partnering strategy best suited to each program.
NovaBridge's portfolio includes programs in oncology and ophthalmology, led by givastomig and VIS-101. The Company's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing innovative therapies to patients through the path best suited to each opportunity.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
NovaBridge Investor & Media Contacts
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
Bill Begien, VP, Investor Relations
bill.begien@novabridge.com
Jessica Zhang, Director, Public Relations
jessica.zhang@novabridge.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.